Long-term safety profile of tolvaptan in autosomal dominant polycystic kidney disease patients: TEMPO Extension Japan Trial

AIM: The aim of this trial (ClinicalTrials.gov identifier: NCT01280721) was to investigate the long-term safety profile of tolvaptan in Japanese patients with autosomal dominant polycystic kidney disease (ADPKD). METHODS: This open-label multicenter trial was conducted to examine adverse drug reacti...

Descripción completa

Detalles Bibliográficos
Autores principales: Muto, Satoru, Okada, Tadashi, Yasuda, Moriyoshi, Tsubouchi, Hidetsugu, Nakajima, Koji, Horie, Shigeo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5661830/
https://www.ncbi.nlm.nih.gov/pubmed/29123425
http://dx.doi.org/10.2147/DHPS.S142825

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5661830/
https://www.ncbi.nlm.nih.gov/pubmed/29123425
http://dx.doi.org/10.2147/DHPS.S142825

Ejemplares similares